Loncar Cancer Immunotherapy Index Announces Merger Replacements Oct 4, 2017 08:00AM
Gilead Sciences Completes Acquisition of Kite Pharma, Inc. Oct 3, 2017 08:45AM
Gilead Sciences (GILD) Completes Tender Offer for Shares of Kite Pharma (KITE) Oct 3, 2017 08:01AM
Gilead Sciences Completes Tender Offer for All Outstanding Shares of Kite Pharma, Inc. Oct 3, 2017 08:00AM
Gilead Sciences (GILD), Kite Pharma (KITE) Announce Expiration of HSR Waiting Period Sep 26, 2017 08:31AM
View Older Stories

Sep 26, 2017 08:30AM Gilead Sciences and Kite Pharma Announce Expiration of Hart-Scott-Rodino Waiting Period
Aug 28, 2017 07:01AM Gilead Sciences (GILD) Announces Agreement to Acquire Kite Pharma (KITE) for $11.9B
Aug 28, 2017 07:00AM Gilead Sciences to Acquire Kite Pharma for $11.9 Billion
Aug 17, 2017 08:34AM Kite Pharma (KITE) Highlights Publication from NCI Demonstrating Responses in Patients with Metastatic Solid Tumors Treated with TCR Therapy Targeting MAGE A3
Aug 17, 2017 08:30AM Kite Highlights Publication from the National Cancer Institute Demonstrating Responses in Patients with Metastatic Solid Tumors Treated with T Cell Receptor (TCR) Therapy Targeting MAGE A3
Aug 8, 2017 08:00AM Kite Reports Second Quarter 2017 Financial Results
Aug 8, 2017 07:47AM Kite Pharma (KITE) Submits IND Application for KITE-585
Aug 8, 2017 07:45AM Kite Submits Investigational New Drug (IND) Application for KITE-585, Anti-BCMA CAR-T Therapy Candidate for Multiple Myeloma
Aug 7, 2017 08:30AM Kite Pharma (KITE) Initiates Axicabtagene Ciloleucel CAR-T Clinical Program in EU
Aug 7, 2017 08:30AM Kite Announces Initiation of Axicabtagene Ciloleucel CAR-T Clinical Program in the European Union
Aug 3, 2017 09:50AM Kite Announces Landmark Study of Refractory Aggressive Non-Hodgkin Lymphoma (SCHOLAR-1) Outcomes Published in the Journal BLOOD
Aug 2, 2017 08:36AM Kite Pharma (KITE) Doses First Patient in Phase 2 Trial of Axicabtagene Ciloleucel in iNHL
Aug 2, 2017 08:30AM Kite Doses First Patient in the Phase 2 Trial of Axicabtagene Ciloleucel in Indolent B-Cell Non-Hodgkin Lymphoma (ZUMA-5)
Aug 1, 2017 08:35AM Kite to Present at August 2017 Investor Conference
Aug 1, 2017 08:30AM Kite to Report Second Quarter 2017 Financial Results on August 8, 2017
Jul 31, 2017 08:34AM Kite Pharma (KITE) Files MAA in Europe for Axicabtagene Ciloleucel
Jul 31, 2017 08:30AM Kite Files the Industry’s First CAR-T Marketing Authorization Application in Europe for Axicabtagene Ciloleucel
Jul 20, 2017 08:33AM Kite Pharma (KITE) Highlights Publishing of Results Showing Durable Complete Remissions Up to 56+ Months in Patients with Chemorefractory Aggressive NHL after Anti-CD19 CAR T-Cell Therapy
Jul 20, 2017 08:30AM Kite Highlights Durable Complete Remissions Up to 56+ Months in Patients with Chemorefractory Aggressive Non-Hodgkin Lymphoma (NHL) after Anti-CD19 CAR T-Cell Therapy at the National Cancer Institute
Jun 28, 2017 08:33AM Kite Pharma (KITE) Says U.S. Patent Office to Confirm Seminal Eshhar CAR-T Patent
Jun 28, 2017 08:30AM U.S. Patent Office to Confirm Kite’s Seminal Eshhar CAR-T Patent
Jun 27, 2017 09:30AM Kite Named to the MIT Technology Review’s Annual 50 Smartest Companies List in Recognition for its Leadership in Establishing CAR-T Therapy
Jun 6, 2017 08:30AM Kite to Present at June 2017 Investor Conferences
Jun 5, 2017 09:01AM Kite Pharma (KITE) Says 73% of Patients Achieved MRD Negative Complete Remission in Updated Analysis From Phase 1 ZUMA-3 CAR-T Trial of KTE-C19 in Adult Patients With High Burden R/R ALL
Jun 5, 2017 09:00AM Kite Reports 73 Percent of Patients Achieved MRD Negative Complete Remission in Updated Analysis From Phase 1 ZUMA-3 CAR-T Trial of KTE-C19 in Adult Patients With High Burden Relapsed/Refractory Acute
May 26, 2017 10:47AM Kite Pharma (KITE) Granted FDA Priority Review for Axicabtagene Ciloleucel
May 26, 2017 10:47AM Kite Receives U.S. Food and Drug Administration Priority Review for Axicabtagene Ciloleucel
May 17, 2017 05:06PM Kite Pharma (KITE) Announces Presentations on Its Lead CAR-T Therapy Development Program at ASCO
May 17, 2017 05:05PM Kite Announces Presentations on Its Lead CAR-T Therapy Development Program at the 2017 American Society of Clinical Oncology Annual Meeting
May 8, 2017 08:00AM Kite Reports First Quarter Financial Results
May 1, 2017 08:30AM Kite to Report First Quarter 2017 Financial Results on May 8, 2017
Apr 6, 2017 08:30AM Kite Wins ‘Clinical Trial Result of the Year’ for its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at the 2017 Clinical and Research Excellence A
Apr 4, 2017 03:37PM Kite Pharma (KITE) Highlights Pre-Clinical Data on KITE-585, a Fully Human Anti-BCMA CAR T-Cell Product Candidate at AACR Meetings
Apr 4, 2017 03:35PM Kite Presents Promising Preclinical Data from KITE-585, a Fully Human Anti-BCMA CAR T-Cell Product Candidate at the 2017 American Association of Cancer Research (AACR) Annual Meeting
Apr 4, 2017 08:30AM Kite Highlights Publication on Breakthrough in Generating Fully Functioning T Cells from Hematopoietic Precursor Cells by Leading Researchers at the University of California, Los Angeles (UCLA)
Apr 3, 2017 06:37AM Kite Pharma (KITE) ZUMA-1 Trial Met Primary Endpoint in Non-Hodgkin Lymphoma
Apr 2, 2017 04:04PM Kite Presents Ongoing Response Rate in Plenary Session from its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at the 2017 American Association of Canc
Mar 31, 2017 03:16PM Kite Pharma (KITE) Completes Submission of U.S. BLA for Axicabtagene Ciloleucel to Treat Patients With Aggressive NHL
Mar 31, 2017 03:15PM Kite Completes Submission of U.S. Biologics License Application (BLA) for Axicabtagene Ciloleucel as the First CAR-T Therapy for the Treatment of Patients With Aggressive Non-Hodgkin Lymphoma (NHL)
Mar 30, 2017 08:32AM Kite Pharma (KITE) Announces Two Plenary Presentations from ZUMA-1 Pivotal Trial of Axicabtagene Ciloleucel at AACR
Mar 30, 2017 08:30AM Kite to Present Two Plenary Presentations from the ZUMA-1 Pivotal Trial of Axicabtagene Ciloleucel at the 2017 American Association of Cancer Research Annual Meeting
Mar 16, 2017 08:30AM Kite Announces Appointment of Renowned Cancer Researcher, Owen N. Witte, M.D., to its Board of Directors
Mar 14, 2017 04:14PM Kite Pharma Highlights Publication from the National Cancer Institute Demonstrating Durable Complete Remissions in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma Following Low Dose Conditionin
Mar 6, 2017 08:30AM Kite to Present at March 2017 Investor Conferences
Mar 5, 2017 04:00PM Richard L. Wang Named Chief Executive Officer of Fosun Kite Biotechnology Co., Ltd., a Joint Venture to Lead Development of Axicabtagene Ciloleucel and Other Engineered T-Cell Therapies for Treatment
Feb 28, 2017 08:00AM Kite Reports Fourth Quarter and Full Year 2016 Financial Results
Feb 28, 2017 07:03AM Kite Pharma (KITE) Reports Positive Topline Data on Axicabtagene Ciloleucel from First Pivotal CAR-T Trial in Patients with Aggressive NHL
Feb 28, 2017 07:00AM Kite Announces Positive Topline Primary Results of Axicabtagene Ciloleucel from First Pivotal CAR-T Trial in Patients with Aggressive Non-Hodgkin Lymphoma
Feb 27, 2017 04:30PM Kite to Report Fourth Quarter and Full Year 2016 Financial Results on February 28, 2017
Jan 10, 2017 03:45AM Kite Pharma (KITE) & Fosun Pharma Establish Chinese Joint Venture, Will Develop And Commercialize Autologous T-Cell Therapies For Cancer Treatment
View Older Stories